BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12010830)

  • 1. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
    Estey EH; Giles FJ; Beran M; O'Brien S; Pierce SA; Faderl SH; Cortes JE; Kantarjian HM
    Blood; 2002 Jun; 99(11):4222-4. PubMed ID: 12010830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
    Estey EH; Giles FJ; Kantarjian H; O'Brien S; Cortes J; Freireich EJ; Lopez-Berestein G; Keating M
    Blood; 1999 Oct; 94(7):2230-5. PubMed ID: 10498593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
    Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
    Estey E; Koller C; Cortes J; Reed P; Freireich E; Giles F; Kantarjian H
    Leuk Lymphoma; 2001 Jul; 42(3):309-16. PubMed ID: 11699395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
    Tsimberidou AM; Tirado-Gomez M; Andreeff M; O'Brien S; Kantarjian H; Keating M; Lopez-Berestein G; Estey E
    Leuk Lymphoma; 2006 Jun; 47(6):1062-8. PubMed ID: 16840198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
    Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
    Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
    Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
    Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
    Escudier SM; Kantarjian HM; Estey EH
    Leuk Lymphoma; 1996 Feb; 20(5-6):435-9. PubMed ID: 8833399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
    Cortes JE; Kantarjian H; O'Brien S; Robertson LE; Koller C; Hirsh-Ginsberg C; Stass S; Keating M; Estey E
    Cancer; 1994 Jun; 73(12):2946-52. PubMed ID: 8199992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan.
    Ohno R; Ohnishi K; Takeshita A; Tanimoto M; Murakami H; Kanamaru A; Asou N; Kobayashi T; Kuriyama K; Ohmoto E
    Leukemia; 1994; 8 Suppl 3():S64-9. PubMed ID: 7808028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura U; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Akiyama H; Tsubaki K; Saito K; Kuriyama K; Oh H; Kitano K; Miyawaki S; Takeyama U; Yamada O; Nishikawa K; Takahashi M; Matsuda S; Ohtake H; Ohno R
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S65-71. PubMed ID: 11587370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
    Thomas X; Dombret H; Cordonnier C; Pigneux A; Gardin C; Guerci A; Vekhoff A; Sadoun A; Stamatoullas A; Fegueux N; Maloisel F; Cahn JY; Reman O; Gratecos N; Berthou C; Huguet F; Kotoucek P; Travade P; Buzyn A; de Revel T; Vilque JP; Naccache P; Chomienne C; Degos L; Fenaux P
    Leukemia; 2000 Jun; 14(6):1006-13. PubMed ID: 10865965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.
    Estey E; Thall PF; Pierce S; Kantarjian H; Keating M
    J Clin Oncol; 1997 Feb; 15(2):483-90. PubMed ID: 9053469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of Idarubicin-Based Stratified Therapy for Acute Promyelocytic Leukemia].
    Guan W; Li WJ; Yang L; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):353-357. PubMed ID: 28446274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols.
    Mandelli F; Latagliata R; Avvisati G; Fazi P; Rodeghiero F; Leoni F; Gobbi M; Nobile F; Gallo E; Fanin R; Amadori S; Vignetti M; Fioritoni G; Ferrara F; Peta A; Giustolisi R; Broccia G; Petti MC; Lo-Coco F;
    Leukemia; 2003 Jun; 17(6):1085-90. PubMed ID: 12764372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
    Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
    Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
    Jurcic JG; DeBlasio T; Dumont L; Yao TJ; Scheinberg DA
    Clin Cancer Res; 2000 Feb; 6(2):372-80. PubMed ID: 10690513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute promyelocytic leukemia relapse in the ATRA era.
    Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
    Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
    Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
    Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.